| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BLVD, SOUTH SAN FRANCISCO | /s/ Brett A. Grimaud, Attorney-in-Fact | 18 Mar 2026 | 0001898490 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TBPH | Ordinary Shares | Sale | $108,088 | -7,767 | -2.9% | $13.92 | 255,999 | 16 Mar 2026 | Direct | F1 |
| transaction | TBPH | Ordinary Shares | Sale | $217,476 | -15,534 | -6.1% | $14.00 | 240,465 | 16 Mar 2026 | Direct | |
| transaction | TBPH | Ordinary Shares | Sale | $108,073 | -7,766 | -3.2% | $13.92 | 232,699 | 16 Mar 2026 | Direct | F1 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | This transaction was executed in multiple trades at prices from $13.755 to $14.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. |
These transactions were executed in accordance with the reporting person's 10b5-1 plan dated 09/03/2025.